Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7251–7300 of 76368
Effective September 16, 2024, Ms. Yuanmei Ma will resign from her positions as Chief Financial Officer and member of the Board of Directors of the Company.
Effective September 16, 2024, Ms. Yuanmei Ma will resign from her positions as Chief Financial Officer and member of the Board of Directors of the Company.
Mr. Stocchetti has now notified the Bank that his retirement will be effective December 31, 2024.
Tim Cabral has resigned from his position as Interim Chief Financial Officer of Veeva.
On August 19, 2024, Christopher T. Oswald, the Senior Vice President of Farmers and Merchants Bancshares, Inc. (the “Company”) and the Executive Vice President - Chief Operations Officer of Farmers and Merchants Bank, the Company’s bank subsidiary, retired.
On September 13, 2024, John North resigned as Chief Executive Officer of Lazydays Holdings, Inc., a Delaware corporation (the “ Company ”), and as a director of the Company.
James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.
James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.
accepted the resignation of Hassan Oulhous as a member of the Company’s Board of Directors.
On October 13, 2023, Farmhouse announced that Mr. Scott Bosick, a member of the Board of Directors, tendered his resignation from the Board, effective immediately.
On September 11, 2024, Rachit Lohani, Senior Vice President and Chief Technology Officer of Paylocity Holding Corporation (the “Company”), notified the Company of his decision to depart the Company.
On September 10, 2024, Jeremy Whitaker informed Lantronix, Inc. (the “Company”) that he was resigning as the Company’s Chief Financial Officer effective September 13, 2024.
Effective August 22, 2024, James Fuller voluntarily resigned as a Director of Cavitation Technologies, Inc. (“Company”) and any committees thereof for personal reasons.
Mr. John Carrington stepped down as Chief Executive Officer of the Company and as a member of the Company’s board of directors (the “Board”), effective September 11, 2024.
On September 15, 2024, Chunyi (Amy) Leong informed SkyWater Technology, Inc. (the “Company”) of her decision to resign from the Company’s Board of Directors (the “Board”) effective September 29, 2024.
Janet Chou, who announced her intention to resign as CFO and Treasurer of the Company, effective October 4, 2024.
Dr. Ford Tamer, a member of the Board of Directors of Marvell Technology, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of September 15, 2024.
On September 10, 2024, Scott Bower notified Pagaya Technologies Ltd. (“Pagaya” or the “Company”) of his resignation as principal accounting officer of the Company, effective September 20, 2024.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.
On September 10, 2024, Trevor I. Mihalik provided notice that he will retire as the Executive Vice President and Group President of Sempra and as the non-executive Chairman of the Board and a director of Southern California Gas Company, a subsidiary of Sempra, in each case effective January 1, 2025.
The Board removed Misty Kawecki as the Company’s Chief Financial Officer at such time.
On September 11, 2024, Ms. Nikita Jaiswal resigned from the board of directors (the “Board”) of Future Health Esg Corp (the “Company”).
Equinix, Inc. (the “Company”) has announced that Scott Crenshaw, the Executive Vice President and General Manager, Digital Services of the Company, will separate from his employment with the Company.
On September 10, 2024, Eva Redhe, an independent director on the Board of Directors of Enphys Acquisition Corp., a Cayman Islands exempted company (the “Company”), informed the Company that she has resigned from the Board of Directors of the Company, including from her committee positions on the audit committee, the compensation committee, and the nominating and corporate governance committee, effective immediately.
On September 9, 2024, 3D Systems Corporation (the “Company”) notified Margaret E. Wicklund that her role and position as the Company’s Senior Vice President and Chief Accounting Officer will be eliminated, effective immediately as part of a planned restructuring within the Company’s finance function.
On September 12, 2024, Fred E. Cohen, M.D., D.Phil., notified UroGen Pharma Ltd. (the “Company”) of his resignation as a director of the Company, effective immediately.
On September 10, 2024, Chrystyna Bedrij Stecyk informed Vaccinex, Inc. (the “Company”) of her resignation as a director of the Company effective immediately.
the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.
On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.
On September 11, 2024, Ms. Nikita Jaiswal resigned from the board of directors (the “Board”) of EVe Mobility Acquisition Corp (the “Company”).
On August 21, 2024, effective August 19, 2024, the Company and Ryan Maarschalk entered into a Termination Agreement pursuant to which Mr. Maarschalk ceased to be Chief Financial Officer of the Company.
As previously announced on February 27, 2024, Kenneth L. Londoner, the former chairperson (“Chairman”) of the Board of Directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) resigned from the Company.
On September 9, 2024, Mr. Bill Bryant resigned from his positions as a director of the board of directors (the " Board ") of the Company
Adrian Kilcoyne, M.D., M.P.H., M.B.A. of Celularity Inc., or Celularity, provided notice of resignation from his role as Executive Vice President and Chief Medical Officer, effective as of August 6, 2024, to pursue other opportunities.
On September 9, 2024, Christian Okonsky resigned as a member of the Volcon, Inc. (the “Company”) Board of Directors (the “Board”).
On September 10, 2024, Forza X1, Inc. (the “Company”) entered into a Separation Agreement with Dan Norton, the Company’s President, pursuant to which Mr. Norton and the Company mutually agreed to terminate his employment with the Company, effective as of September 30, 2024 (the “Separation Agreement”).
On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.
This appointment takes effect following the conclusion of Michael DiTullio’s tenure as President and Chief Operating Officer of the Company on September 30, 2024.
Salim Yazji, M.D. will cease serving as Chief Medical Officer, to be effective as of October 1, 2024.
Ann M. Powell informed the Company of her decision not to stand for election to the Board of Directors of the Company at the Meeting.
On September 11, 2024, Michelle Swanback, president of TTEC Holdings, Inc. (“TTEC”) and TTEC Engage business segment’s chief executive officer, notified the company that she is resigning, effective December 31, 2024.
terminated Alan H. Shaw, President and Chief Executive Officer of the Company, in connection with preliminary findings from an ongoing investigation conducted by independent counsel that determined Shaw violated Company policies by engaging in a consensual relationship with the Company’s Chief Legal Officer.
On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.
who on July 8, 2024, informed the Company of his intention to retire as an officer of the Company.
On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.
Pursuant to the Settlement Agreement, Mr. Khurshid advised the Company that he was resigning as Chief Executive Officer and as a director of the Company effective September 4, 2024.
Pursuant to the Settlement Agreement, Mr. Khurshid advised the Company that he was resigning as Chief Executive Officer and as a director of the Company effective September 4, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.